A Phase 2 interventional study of Exemestane and Celecoxib + Exemestane in Breast Neoplasms, sponsored by Pfizer. Completed at 20 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-25.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing celecoxib in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Celecoxib · Breast Neoplasms.
Among the 23 studies testing celecoxib in Breast Neoplasms, this one is the 3rd largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2002, is one of 13 in phase 2, and was the 2nd registered.
14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →None of the 23 studies testing celecoxib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 3
First in 2000; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 42 across the 19 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 49th largest by enrollment of the 121 interventional ones that give a count, is one of 8 that started in 2002, is one of 43 in phase 2, and was the 4th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing celecoxib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Exemestane
Drug: Celecoxib + Exemestane
Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
Also known as: Aromasin
Drug pages: CelecoxibStudies of CelecoxibCelecoxib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
Also known as: Celebrex, Aromasin
Number of Subjects With Clinical Benefit
Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation. Includes subjects with complete response (CR), partial response (PR), and long term disease stabilization (SD) for at least 24 weeks.
Time frame: Baseline, Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV)
Number of Subjects With Objective Response
Objective tumor response includes subjects with CR or PR according to RECIST.
Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Duration of Clinical Benefit
Time from randomization date to first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression.
Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Duration of Objective Response (in Subjects With CR or PR)
Time from the first objective documentation of response until the first objective documentation of tumor progression.
Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks beyond 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Duration of Long-Term SD
Time from start of treatment until the first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression in subjects with long-term SD.
Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months LSLV
Time to Tumor Progression
Time from randomization to first objective tumor recurrence or progression or death due to tumor progression in the absence of previous documentation of tumor progression.
Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks beyond Week 24 up to Week 108 and every 24 weeks thereafter until 9 months following LSLV
Time to Treatment Failure
Time from randomization to first objective tumor recurrence or progression or death due to any cause or withdrawal from study treatment due to any reason, whichever was the earliest.
Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV
Survival
Time from randomization to date of death (any cause).
Time frame: Baseline, Weeks 8, 16, 24, every 12 weeks from Week 24 up to Week 108, and every 24 weeks thereafter until 9 months following LSLV or death
| Milestone | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Started | 55 | 56 |
| End of treatment | 53 | 56 |
| Completed | 0 | 0 |
| Not completed | 55 | 56 |
| Withdrew: Adverse event | 5 | 6 |
| Withdrew: Lack of efficacy | 48 | 41 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Randomized/never treated | 2 | 0 |
Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation. Includes subjects with complete response (CR), partial response (PR), and long term disease stabilization (SD) for at least 24 weeks.
| participants | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Number of Subjects With Clinical Benefit | 24 | 24 |
Objective tumor response includes subjects with CR or PR according to RECIST.
| participants | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Number of Subjects With Objective Response | 11 | 12 |
Time from randomization date to first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression.
| weeks | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Duration of Clinical Benefit | 49.1 (37.0 to 85.0) | 96.6 (37.0 to 147.0) |
Time from the first objective documentation of response until the first objective documentation of tumor progression.
| weeks | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Duration of Objective Response (in Subjects With CR or PR) | 32.7 (23.1 to 68.9) | 40.1 (28.3 to 169.1) |
Time from start of treatment until the first objective documentation of tumor progression or death due to tumor progression in the absence of previous documentation of tumor progression in subjects with long-term SD.
| weeks | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Duration of Long-Term SD | 52.9 (36.6 to 110.0) | 109.7 (36.6 to 147.0) |
Time from randomization to first objective tumor recurrence or progression or death due to tumor progression in the absence of previous documentation of tumor progression.
| weeks | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Time to Tumor Progression | 20 (9.4 to 36.6) | 23.4 (16.3 to 36.9) |
Time from randomization to first objective tumor recurrence or progression or death due to any cause or withdrawal from study treatment due to any reason, whichever was the earliest.
| Weeks | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Time to Treatment Failure | 18.1 (9.3 to 36.6) | 20.4 (14.9 to 34.6) |
Time from randomization to date of death (any cause).
| weeks | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Survival | 74.4 (57.7 to 101.4) | 73.9 (52.3 to 106.7) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Exemestane (Exemestane Alone) | — | — | — |
| Combination (Exemestane + Celecoxib) | — | — | — |
| Event | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/53 | 3/56 |
| JaundiceHepatobiliary disorders | 2/53 | 0/56 |
| VomitingGastrointestinal disorders | 2/53 | 0/56 |
| AstheniaGeneral disorders | 2/53 | 0/56 |
| PainGeneral disorders | 1/53 | 1/56 |
| Post procedural complicationReproductive system and breast disorders | 1/53 | 0/56 |
| DeathGeneral disorders | 1/53 | 1/56 |
| AscitesGastrointestinal disorders | 1/53 | 0/56 |
| NauseaGastrointestinal disorders | 1/53 | 0/56 |
| General physical health deteriorationGeneral disorders | 1/53 | 1/56 |
| Event | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 8/53 | 10/53 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/53 | 4/53 |
| VomitingGastrointestinal disorders | 8/53 | 2/53 |
| Hot flushVascular disorders | 6/53 | 8/53 |
| AnorexiaMetabolism and nutrition disorders | 7/53 | 3/53 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 7/53 | 5/53 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/53 | 7/53 |
| AstheniaGeneral disorders | 4/53 | 6/53 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/53 | 6/53 |
| DiarrhoeaGastrointestinal disorders | 3/53 | 5/53 |
| Age, Customized(Participants) | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) | Total |
|---|---|---|---|
| < 50 years | 20.0 | 16.0 | 36.0 |
| 50-64 years | 20.0 | 27.0 | 47.0 |
| 65-79 years | 15.0 | 12.0 | 27.0 |
| => 80 years | 0.0 | 1.0 | 1.0 |
| Sex: Female, Male(Participants) | Exemestane (Exemestane Alone) | Combination (Exemestane + Celecoxib) | Total |
|---|---|---|---|
| Female | 55 | 56 | 111.0 |
| Male | 0 | 0 | 0.0 |
The record gives a start of Jan 2002, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Celecoxib · Exemestane